AGM Statement

Evgen Pharma plc

 ("Evgen" or "the Company")

AGM Statement

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will hold its Annual General Meeting ("AGM") later today. At the AGM, the Company's Chairman, Barry Clare, will make the following statement.

"We continue to make significant progress in establishing Evgen as a world leader in sulforaphane-based pharmaceuticals.

"In March this year we announced that our lead product, SFX-01, had met its primary endpoints in an open label Phase 2 trial of SFX-01 in metastatic breast cancer. The trial data confirmed that SFX-01 is a highly promising anti-cancer agent with an excellent tolerability profile. We are making good progress in planning the next clinical trial in metastatic breast cancer, focusing on the anticipated use of SFX-01 as a second line therapy where the market opportunity is substantial.

"The announcement of the final read-out of our Phase 2 trial of SFX-01 in subarachnoid haemorrhage remains in line with earlier guidance of Q3 or early Q4 of this calendar year. We are excited by the outcome of this blinded study in an indication where there has been no significant clinical advance in more than 20 years.

"Further anticipated near-term news flow includes the announcement of secondary data and additional insights from the metastatic breast cancer trial at the ESMO 2019 conference in Barcelona in the early autumn.

 "The £5m equity placing completed earlier this year has given us the financial resources to support the continued development of our programmes, in particular, further toxicology work to enable support for investigator-led clinical trials, and a scale-up ready product formulation, giving us confidence in the year ahead."

A short presentation will be given to shareholders at the AGM. The presentation will contain no new material information and will be made available later today on the Company website, here:

http://evgen.com/investors/shareholder-information/

Separately, we would like to announce that Evgen has appointed Walbrook PR and, from hereon in, they will be supporting our PR efforts as we enter the next stage of our development. We are very grateful to Buchanan for the strong support they have provided over the past few years.

Enquiries:

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke.  The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane.  The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

The Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com